acute myeloid leukemia News
-
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced the publication of preclinical data in the peer-reviewed journal Cancer Immunology, Immunotherapy, for its lead clinical oncology program, RTX-240, for the ...
-
Agilent Technologies Introduces Next-Generation Sequencing Cancer Research Panels
Agilent Technologies Inc. (NYSE: A) today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia. Designed in collaboration with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University, ClearSeq ...
-
Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors
Phase 1 multicenter dose-escalation and dose-expansion trial evaluating IO-202 as a monotherapy and in combination with an anti-PD-1 is initiated and expected to enroll 200 patientswith advanced solid tumors This is the second clinical trial for the IO-202 program; its first Phase 1 trial is currently enrolling patients with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia ...
-
Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests
Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells ...
-
Senti Bio to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that co-founders Tim Lu, MD, PhD, Chief Executive Officer, and Philip Lee, PhD, Chief Technology Officer, will participate in a Fireside Chat at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 25, 2022 at 3:00 p.m. ET. Senti Bio uses its Gene ...
-
Senti Bio to Present Data from Gene Circuit-Engineered Allogeneic CAR-NK Cell Therapy Pipeline at Upcoming Scientific Conferences
Three ASGCT abstracts highlight new data related to application of gene circuit technology to enhance efficacy and safety of cancer-killing CAR-NK cells ISCT abstract describes scalable, reproducible, cGMP-ready CAR-NK manufacturing process to support planned clinical development of oncology pipeline candidates Senti Bio, a leading gene circuit company, today announced the acceptance of ...
-
Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that data from the Company’s compassionate use program on anti-leukemic activity of STRO-002, a novel folate receptor-α (FR-α) targeting ADC, in infants and children with relapsed/refractory ...
-
Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder, will present a corporate overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 2:00 p.m. EST. Senti Bio uses its Gene Circuit platform to program cell and gene therapies with potentially ...
-
Senti Bio Highlights Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells in Three Presentations at ASGCT Annual Meeting
SENTI-202 oral presentation details systematic optimization of Logic Gating Gene Circuit technology in allogeneic CAR-NK cells to more precisely target tumor cells in acute myeloid leukemia, while sparing healthy cells SENTI-301 poster presentation highlights optimization of Multi-Arming and Regulator Dial Gene Circuits to improve the cytotoxicity of allogeneic CAR-NK cells and immune ...
-
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the details of its webcast to discuss updated clinical data from the ongoing monotherapy Phase 1 arm of ...
-
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapies First preclinical data set on the combination of AFM28 with natural killer cells, both in co-administration or pre-complexed, demonstrates cytotoxic activity against CD123-positive tumor cells Heidelberg, Germany, May 16, 2022 – Affimed N.V. ...
By Affimed GmbH
-
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an AML murine model demonstrated anti-tumor efficacy; ...
By Affimed GmbH
-
Senti Bio Presents New Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of allogeneic CAR-NK cells for the treatment of solid tumors CAR-NK cells armed with calibrated release IL-15 achieve optimal cytokine distribution and result in superior killing and persistence Senti Bio, a leading gene circuit company, today announced new data from preclinical studies that further ...
-
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to be Presented in a Poster at the American Association of Cancer Research Annual Meeting on Tuesday, April 12, 2022, from 9:00 a.m. – 12:30 p.m. ET Management to Host Investor Webcast to Discuss RTX-240 Single-Agent Results in Advanced Solid Tumors and Acute Myeloid Leukemia (AML) Along with ...
-
Cellworks Personalized Therapy Biosimulation Study Identifies Novel Biomarkers Predictive of Response in AML Patients
Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from a clinical study using the Cellworks Biosimulation Platform and Computational Omics Biology Model (CBM) to predict therapy response for individual Acute Myeloid Leukemia (AML) patients were featured in a poster presentation at the 63rd American ...
-
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 20-23, 2021. The presentation will provide an overview of the ...
-
Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. The presentation will provide an overview of the Company’s ...
-
Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development Officer
Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced the appointment of Kanya Rajangam, MD, PhD, as Chief Medical and Development Officer. Dr. Rajangam, who will join the company this July, is an experienced biotechnology executive with an extensive track record of successfully developing cancer therapies across multiple modalities. Senti Bio is developing ...
-
Immune-Onc Therapeutics Enters into Clinical Collaboration with BeiGene in China
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced it has entered into a clinical trial collaboration and supply agreement with to evaluate Immune-Onc’s first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with ...
-
Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)
Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET -AML test for early detection of acute myeloid leukemia (AML) in patients with myelodysplastic syndrome ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you